Resources | Adimab

Potent T Cell-Engaging (TCE) Single-Domain Antibodies that Cross-React with Non-Human Primate (NHP) T Cell Receptor (TCR) Constant Region αβ as an Alternative to CD3 Engagement

Potent T Cell-Engaging (TCE) Single-Domain Antibodies that Cross-React with Non-Human Primate (NHP) T Cell Receptor (TCR) Constant Region αβ as an Alternative to CD3 Engagement

TCR-targeting VHHs enable orthogonal T cell activation with strong cytotoxicity and species cross-reactivity

Filters

Resources

Therapeutic Area

Capabilities

Resources

Schematic of Chain Exchange reaction

loading="lazy">

Chain Exchange Technology: Enabling Efficient Bispecific and Complex Multispecific Antibody Generation

Enabling high-purity assembly without complex purification to support rapid format exploration of multispecifics

Graph showing variation in Raji cell killing with increasing bispecific antibody concentration for a variety of bispecifics

loading="lazy">

Discovery and Engineering of T Cell Engagers (TCEs) using Adimab’s platform

Systematic TCE exploration using tunable CD3/CD28 panels and rapid format screening optimizes efficacy

Correct assembly of multispecific antibodies

loading="lazy">

Leveraging complementary technologies to generate diverse, developable multispecific antibodies

Systematic exploration of multispecific geometries facilitates identification of optimal architecture

Adimab's yeast-based platform for high-throughput engineering of soluble TCR-Fc molecules

loading="lazy">

Mon 10 Nov 2025

High-Throughput Engineering of Soluble TCRs Using Adimab’s Yeast-Based Platform

Data-driven yeast platform delivers potent, peptide-specific TCRs ready for therapeutic development.

Resources